Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Diflorasone
2. Florone
3. Flutone
4. Maxiflor
5. Psorcon
6. Psorcon E
1. 33564-31-7
2. Psorcon
3. Florone E
4. Maxiflor
5. Apexicon E
6. Diflorasone Di(acetate)
7. 7w2j09scwx
8. Mls000069559
9. Mls001076548
10. [2-[(6s,8s,9r,10s,11s,13s,14s,16s,17r)-17-acetyloxy-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] Acetate
11. 6alpha,9-difluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17,21-diacetate
12. Chebi:31483
13. U-34865
14. U-34,865
15. Ncgc00022003-03
16. Smr000058814
17. Psorcon E
18. Dsstox_cid_25646
19. Dsstox_rid_81024
20. Dsstox_gsid_45646
21. Apexicon
22. 2-((6s,8s,9r,10s,11s,13s,14s,16s,17r)-17-acetoxy-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl Acetate
23. 6alpha-fluorobetamethasone-17,21 Diacetate
24. Einecs 251-575-1
25. Unii-7w2j09scwx
26. Brn 2318163
27. Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6.alpha.,11.beta.,16.beta.)-
28. Florone (tn)
29. Psorcon (tn)
30. Cas-33564-31-7
31. Diflorasone Diacetate [usan:usp:jan]
32. Acetic Acid Diflorasone
33. Opera_id_1660
34. Prestwick0_000619
35. Prestwick1_000619
36. Prestwick2_000619
37. Prestwick3_000619
38. Schembl4556
39. Bspbio_000558
40. Diflorasone 17,21-diacetate
41. Regid_for_cid_71414
42. Spbio_002777
43. Bpbio1_000614
44. Gtpl7068
45. Chembl1200545
46. Dtxsid8045646
47. Diflorasone Diacetate [mi]
48. Hms1569l20
49. Hms2096l20
50. Hms2231d10
51. Hms3713l20
52. Diflorasone Diacetate (jp17/usp)
53. Diflorasone Diacetate [jan]
54. 6.alpha.,9-difluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17,21-diacetate
55. Zinc4212938
56. Diflorasone Diacetate [usan]
57. Tox21_110875
58. Diflorasone Diacetate [vandf]
59. Diflorasone Diacetate [mart.]
60. Akos025402039
61. Diflorasone Diacetate [usp-rs]
62. Diflorasone Diacetate [who-dd]
63. Tox21_110875_1
64. Ac-3515
65. Bcp9000608
66. Ccg-220619
67. Nsc 759267
68. Ncgc00022003-04
69. Ncgc00022003-06
70. (6alpha,11beta,16beta)-6,9-difluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl Diacetate
71. Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6alpha,11beta,16beta)-
72. Diflorasone Diacetate [orange Book]
73. Diflorasone Diacetate [usp Impurity]
74. Hy-107961
75. Ab00489907
76. Cs-0031025
77. Diflorasone Diacetate [usp Monograph]
78. D01327
79. E98631
80. Diflorasone Diacetate 100 Microg/ml In Methanol
81. 564d317
82. A821840
83. Sr-01000000122
84. Q-101374
85. Sr-01000000122-3
86. Brd-k17674993-001-03-1
87. Q27881705
88. Diflorasone Diacetate, United States Pharmacopeia (usp) Reference Standard
89. [2-[(6s,8s,9r,10s,11s,13s,14s,16s,17r)-17-acetyloxy-6,9-bis(fluoranyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxidanylidene-ethyl] Ethanoate
90. 6alpha,9-difluoro-11beta-hydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl Diacetate
91. Acetic Acid [2-[(6s,8s,9r,10s,11s,13s,14s,16s,17r)-17-acetyloxy-6,9-difluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] Ester
92. Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6,alpha.,11.beta.,16.beta.)-
Molecular Weight | 494.5 g/mol |
---|---|
Molecular Formula | C26H32F2O7 |
XLogP3 | 3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 6 |
Exact Mass | 494.21160968 g/mol |
Monoisotopic Mass | 494.21160968 g/mol |
Topological Polar Surface Area | 107 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 1050 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 9 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Diflorasone diacetate |
Drug Label | Each gram of psorcon Ointment contains 0.5 mg diflorasone diacetate in an ointment base. Chemically, diflorasone diacetate is 6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-diacetate. The structural formula is repre... |
Active Ingredient | Diflorasone diacetate |
Dosage Form | Ointment; Cream |
Route | Topical |
Strength | 0.05% |
Market Status | Prescription |
Company | Fougera Pharms; Taro |
2 of 2 | |
---|---|
Drug Name | Diflorasone diacetate |
Drug Label | Each gram of psorcon Ointment contains 0.5 mg diflorasone diacetate in an ointment base. Chemically, diflorasone diacetate is 6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21-diacetate. The structural formula is repre... |
Active Ingredient | Diflorasone diacetate |
Dosage Form | Ointment; Cream |
Route | Topical |
Strength | 0.05% |
Market Status | Prescription |
Company | Fougera Pharms; Taro |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A CAS-33564-31-7 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAS-33564-31-7, including repackagers and relabelers. The FDA regulates CAS-33564-31-7 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAS-33564-31-7 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAS-33564-31-7 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAS-33564-31-7 supplier is an individual or a company that provides CAS-33564-31-7 active pharmaceutical ingredient (API) or CAS-33564-31-7 finished formulations upon request. The CAS-33564-31-7 suppliers may include CAS-33564-31-7 API manufacturers, exporters, distributors and traders.
click here to find a list of CAS-33564-31-7 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAS-33564-31-7 DMF (Drug Master File) is a document detailing the whole manufacturing process of CAS-33564-31-7 active pharmaceutical ingredient (API) in detail. Different forms of CAS-33564-31-7 DMFs exist exist since differing nations have different regulations, such as CAS-33564-31-7 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A CAS-33564-31-7 DMF submitted to regulatory agencies in the US is known as a USDMF. CAS-33564-31-7 USDMF includes data on CAS-33564-31-7's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The CAS-33564-31-7 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of CAS-33564-31-7 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The CAS-33564-31-7 Drug Master File in Japan (CAS-33564-31-7 JDMF) empowers CAS-33564-31-7 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the CAS-33564-31-7 JDMF during the approval evaluation for pharmaceutical products. At the time of CAS-33564-31-7 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of CAS-33564-31-7 suppliers with JDMF on PharmaCompass.
A CAS-33564-31-7 CEP of the European Pharmacopoeia monograph is often referred to as a CAS-33564-31-7 Certificate of Suitability (COS). The purpose of a CAS-33564-31-7 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of CAS-33564-31-7 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of CAS-33564-31-7 to their clients by showing that a CAS-33564-31-7 CEP has been issued for it. The manufacturer submits a CAS-33564-31-7 CEP (COS) as part of the market authorization procedure, and it takes on the role of a CAS-33564-31-7 CEP holder for the record. Additionally, the data presented in the CAS-33564-31-7 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the CAS-33564-31-7 DMF.
A CAS-33564-31-7 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. CAS-33564-31-7 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of CAS-33564-31-7 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CAS-33564-31-7 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for CAS-33564-31-7 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture CAS-33564-31-7 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain CAS-33564-31-7 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CAS-33564-31-7 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of CAS-33564-31-7 suppliers with NDC on PharmaCompass.
CAS-33564-31-7 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAS-33564-31-7 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAS-33564-31-7 GMP manufacturer or CAS-33564-31-7 GMP API supplier for your needs.
A CAS-33564-31-7 CoA (Certificate of Analysis) is a formal document that attests to CAS-33564-31-7's compliance with CAS-33564-31-7 specifications and serves as a tool for batch-level quality control.
CAS-33564-31-7 CoA mostly includes findings from lab analyses of a specific batch. For each CAS-33564-31-7 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAS-33564-31-7 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAS-33564-31-7 EP), CAS-33564-31-7 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAS-33564-31-7 USP).
LOOKING FOR A SUPPLIER?